Stryker (SYK) Q2 Revenue Jumps 11%
(NYSE:SYK), a leading global medical technology company, reported financial results on July 31, 2025. The company delivered several key beats: Net sales (GAAP) reached $6.0 billion, topping analyst expectations of $5.94 billion (GAAP), and adjusted earnings per share (non-GAAP) came in at $3.13, ahead of the $3.07 non-GAAP consensus. This performance reflected double-digit growth in both sales and profits compared to the same period last year. Stryker also raised its full-year 2025 guidance for organic net sales growth and adjusted earnings per share, now expecting organic net sales growth of 9.5% to 10.0% and adjusted net earnings per diluted share of $13.40 to $13.60, reflecting continued momentum in its product lines. The quarter was marked by strong demand in core MedSurg and Neurotechnology segments, additional gains from acquisitions, and further product innovations, although the company faced higher operating expenses and ongoing regulatory and tariff costs.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Stryker is one of the world's largest medical device companies, focusing on products used in surgery, orthopedics, and a broad range of hospital and medical care settings. It is known for its innovation in medical technology, spanning items such as surgical instruments, orthopedic implants, endoscopy equipment, robotic surgery systems, and advanced patient monitoring devices.
Source Fool.com
Stryker Corp. Stock
With 24 Buy predictions and not a single Sell prediction Stryker Corp. is an absolute favorite of our community.
With a target price of 407 € there is a positive potential of 34.9% for Stryker Corp. compared to the current price of 301.7 €.
